March 26, 2020
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics ...
Read more
Read more
March 25, 2020
Orexo has repurchased 14 percent of own corporate bonds
Uppsala, Sweden – March 25, 2020. Orexo AB (publ.) has repurchased 14 percent of its outstanding unsecured corporate bonds with a nominal value of SEK 40,500,000 through ...
Read more
Read more
March 24, 2020
The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)
Stockholm — March 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in r...
Read more
Read more
March 23, 2020
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors
PHILADELPHIA, March 23, 2020 /PRNewswire/ -- Carisma Th...
Read more
Read more
March 23, 2020
Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical Officer
Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as p...
Read more
Read more
March 23, 2020
Dr. Matthias Friebe joins Camel-IDS as acting Chief Technology Officer
Brussels (Belgium), 23 March 2020
Brussels, Belgium – Camel-IDS, a private biotechnology company developing novel radioligand therapies in oncology, announces t...
Read more
Read more
March 23, 2020
Accelerated road to market approval for CERAMENT® G in the US – BONESUPPORT[TM] submits De Novo application
Lund, Sweden, 8 am CET, 23 March 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company will sub...
Read more
Read more
March 23, 2020
Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer
Oslo, Norway, 23 March 2020
Nordic Nanovector ASA (OSE: NANO) announces that Dr Dominic Smethurst has been appointed Interim Chief Medical Officer with immediate effec...
Read more
Read more
March 20, 2020
Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program
STOCKHOLM — March 20, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronav...
Read more
Read more
March 20, 2020
Vicore informs on clinical programs in relation to the current outbreak of COVID-19
Gothenburg, March 20, 2020 – Vicore Pharma informs on clinical programs in relation to the current outbreak of COVID-19.
The on-going clinical study of Raynaud’s pheno...
Read more
Read more